Quarterly report [Sections 13 or 15(d)]

EQUITY

v3.25.2
EQUITY
 6 Months Ended
Jun. 30, 2025
Equity [Abstract]  
Equity EQUITY
Accumulated Other Comprehensive Income (Loss)
The following table presents changes in the components of AOCI, net of taxes, for the six months ended June 30, 2025:
Cash Flow Hedge Cumulative Foreign Currency Translation Adjustments Total
(in thousands)
Balance at December 31, 2024 $ 21,518  $ (356,630) $ (335,112)
Other comprehensive income (loss) before reclassifications
 (1,253) 190,815  189,562 
Amount reclassified from AOCI (6,896) —  (6,896)
Net other comprehensive income (loss) (8,149) 190,815  182,666 
Balance at June 30, 2025 $ 13,369  $ (165,815) $ (152,446)
Earnings Per Share
Basic net income per common share is computed by dividing the net income available to common stockholders by the weighted average number of common shares outstanding during the period. The calculation of diluted net income per common share includes the effects of the assumed exercise of any outstanding stock options, the assumed vesting of shares of restricted and deferred stock awards and the assumed conversion of our convertible senior notes, where dilutive.
The following table sets forth the computation of weighted average common shares outstanding:
Three Months Ended
June 30,		 Six Months Ended
June 30,
2025 2024 2025 2024
Weighted average common shares—basic 231,845,412  229,921,527  231,534,852  229,696,356 
Effect of dilutive securities:
    Stock options and restricted stock 2,572,016  2,076,808  2,930,952  2,327,958 
    Convertible senior notes —  13,004,660  192,804  — 
Weighted average common shares—diluted 234,417,428  245,002,995  234,658,608  232,024,314 
The following table shows securities excluded from the calculation of diluted net income per common share because such securities are anti-dilutive:
Three Months Ended
June 30,		 Six Months Ended
June 30,
2025 2024 2025 2024
Options to purchase shares of common stock —  3,750  —  3,750 
Restricted stock and deferred stock—unvested 1,188,300  2,464,785  1,188,300  2,743,310 
Conversion shares related to the convertible senior notes 14,946,450  —  14,946,450  13,004,660 
Number of anti-dilutive potentially issuable shares excluded from diluted common shares outstanding 16,134,750  2,468,535  16,134,750  15,751,720 
Transactions with Noncontrolling Interest Partners
During the three months ended June 30, 2025, we paid $122.2 million to purchase a portion of the noncontrolling interest in certain subsidiaries in Europe.